These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 37064869)

  • 1. Transformable prodrug nanoplatform
    Yang W; Yi J; Zhu R; Guo Y; Zhang K; Cao Y; Li X; Zhang J; Zhang Z; Li Y; Chen X
    Theranostics; 2023; 13(6):1906-1920. PubMed ID: 37064869
    [No Abstract]   [Full Text] [Related]  

  • 2. A Triple-Responsive Polymeric Prodrug Nanoplatform with Extracellular ROS Consumption and Intracellular H
    Li Y; Cao Y; Ma K; Ma R; Zhang M; Guo Y; Song H; Sun N; Zhang Z; Yang W
    Adv Healthc Mater; 2024 Jun; 13(16):e2303568. PubMed ID: 38319010
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phenolic immunogenic cell death nanoinducer for sensitizing tumor to PD-1 checkpoint blockade immunotherapy.
    Xie L; Wang G; Sang W; Li J; Zhang Z; Li W; Yan J; Zhao Q; Dai Y
    Biomaterials; 2021 Feb; 269():120638. PubMed ID: 33421711
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy.
    Kim J; Shim MK; Moon Y; Kim J; Cho H; Yun WS; Shim N; Seong JK; Lee Y; Lim DK; Kim K
    J Nanobiotechnology; 2024 Mar; 22(1):109. PubMed ID: 38481326
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tumor microenvironment-activated therapeutic peptide-conjugated prodrug nanoparticles for enhanced tumor penetration and local T cell activation in the tumor microenvironment.
    Zhu X; Li C; Lu Y; Liu Y; Wan D; Zhu D; Pan J; Ma G
    Acta Biomater; 2021 Jan; 119():337-348. PubMed ID: 33166712
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Dual functional immunostimulatory polymeric prodrug carrier with pendent indoximod for enhanced cancer immunochemotherapy.
    Wan Z; Sun J; Xu J; Moharil P; Chen J; Xu J; Zhu J; Li J; Huang Y; Xu P; Ma X; Xie W; Lu B; Li S
    Acta Biomater; 2019 May; 90():300-313. PubMed ID: 30930305
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sequentially pH-Responsive Drug-Delivery Nanosystem for Tumor Immunogenic Cell Death and Cooperating with Immune Checkpoint Blockade for Efficient Cancer Chemoimmunotherapy.
    Jiang M; Chen W; Yu W; Xu Z; Liu X; Jia Q; Guan X; Zhang W
    ACS Appl Mater Interfaces; 2021 Sep; 13(37):43963-43974. PubMed ID: 34506118
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tumor microenvironment reprogramming combined with immunogenic enhancement by nanoemulsions potentiates immunotherapy.
    Shen W; Li Y; Yang Z; Li W; Cao Y; Liu Y; Wang Z; Pei R; Xing C
    J Nanobiotechnology; 2024 Apr; 22(1):154. PubMed ID: 38581017
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Crizotinib prodrug micelles co-delivered doxorubicin for synergistic immunogenic cell death induction on breast cancer chemo-immunotherapy.
    Liang Q; Lan Y; Li Y; Cao Y; Li J; Liu Y
    Eur J Pharm Biopharm; 2022 Aug; 177():260-272. PubMed ID: 35863668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tumor Microenvironment-Activatable Prodrug Vesicles for Nanoenabled Cancer Chemoimmunotherapy Combining Immunogenic Cell Death Induction and CD47 Blockade.
    Zhou F; Feng B; Yu H; Wang D; Wang T; Ma Y; Wang S; Li Y
    Adv Mater; 2019 Apr; 31(14):e1805888. PubMed ID: 30762908
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A prodrug hydrogel with tumor microenvironment and near-infrared light dual-responsive action for synergistic cancer immunotherapy.
    Ding M; Fan Y; Lv Y; Liu J; Yu N; Kong D; Sun H; Li J
    Acta Biomater; 2022 Sep; 149():334-346. PubMed ID: 35779775
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tandem Chemoimmunotherapy by a Cascade-Responsive Molecular Prodrug.
    Yang Z; Luo X; Lin Y; Huang J; Lin H; Gao J
    ACS Chem Biol; 2022 Apr; 17(4):762-767. PubMed ID: 35285234
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-PD-L1 peptide-conjugated prodrug nanoparticles for targeted cancer immunotherapy combining PD-L1 blockade with immunogenic cell death.
    Moon Y; Shim MK; Choi J; Yang S; Kim J; Yun WS; Cho H; Park JY; Kim Y; Seong JK; Kim K
    Theranostics; 2022; 12(5):1999-2014. PubMed ID: 35265195
    [No Abstract]   [Full Text] [Related]  

  • 14. Injectable Reactive Oxygen Species-Responsive SN38 Prodrug Scaffold with Checkpoint Inhibitors for Combined Chemoimmunotherapy.
    Gong Y; Chen M; Tan Y; Shen J; Jin Q; Deng W; Sun J; Wang C; Liu Z; Chen Q
    ACS Appl Mater Interfaces; 2020 Nov; 12(45):50248-50259. PubMed ID: 33135879
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pH-responsive Pickering Nanoemulsion for specified spatial delivery of Immune Checkpoint Inhibitor and Chemotherapy agent to Tumors.
    Jia L; Pang M; Fan M; Tan X; Wang Y; Huang M; Liu Y; Wang Q; Zhu Y; Yang X
    Theranostics; 2020; 10(22):9956-9969. PubMed ID: 32929327
    [No Abstract]   [Full Text] [Related]  

  • 16. Cyclic amplification of intracellular ROS boosts enzymatic prodrug activation for enhanced chemo-immunotherapy.
    Liu Y; Jiang M; Zhao Z; Wang N; Wang K; Yuan Y
    Acta Biomater; 2023 Aug; 166():567-580. PubMed ID: 37207741
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Polymeric indoximod based prodrug nanoparticles with doxorubicin entrapment for inducing immunogenic cell death and improving the immunotherapy of breast cancer.
    Zang X; Song J; Yi X; Piyu J
    J Mater Chem B; 2022 Mar; 10(12):2019-2027. PubMed ID: 35254372
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Breast Cancer Chemo-immunotherapy through Liposomal Delivery of an Immunogenic Cell Death Stimulus Plus Interference in the IDO-1 Pathway.
    Lu J; Liu X; Liao YP; Wang X; Ahmed A; Jiang W; Ji Y; Meng H; Nel AE
    ACS Nano; 2018 Nov; 12(11):11041-11061. PubMed ID: 30481959
    [TBL] [Abstract][Full Text] [Related]  

  • 19. An ultrasound-activated nanoplatform remodels tumor microenvironment through diverse cell death induction for improved immunotherapy.
    Ma J; Yuan H; Zhang J; Sun X; Yi L; Li W; Li Z; Fu C; Zheng L; Xu X; Wang X; Wang F; Yin D; Yuan J; Xu C; Li Z; Peng X; Wang J
    J Control Release; 2024 Jun; 370():501-515. PubMed ID: 38703950
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Aptamer-conjugated nano-liposome for immunogenic chemotherapy with reversal of immunosuppression.
    Kim M; Lee JS; Kim W; Lee JH; Jun BH; Kim KS; Kim DE
    J Control Release; 2022 Aug; 348():893-910. PubMed ID: 35760233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.